Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

Boehringer Ingelheim starts clinical development of second Ablynx nanobody

Written by LVS on in the category news with the tags .


Nanobody producer Ablynx has received an €8 million milestone payment from longtime partner Boehringer Ingelheim. The German pharmaceutical heavyweight has started a phase I clinical trial with an anti-CX3CR1 nanobody developed at Ablynx. The nanobody’s target, CX3CR1 is a G-protein coupled receptor (GPCR) difficult to address with conventional antibodies. By inhibiting CX3CR1, the activity of inflammatory immune cells can be attenuated. Currently, the therapeutic nanobody is intended for use in chronic kidney disease, an inflammatory disorder affecting 8-16% of the world’s population.

The anti-CX3CR1 nanobody is the second from the Ablynx-Boehringer collaboration to enter development, after the bispecific anti-VEGF/Ang2 nanobody started its phase I trial last January. Ablynx and Boehringer-Ingelheim started their strategic alliance in 2007 and can earn Ablynx up to €125 million in milestone payments. To date, the collaboration already earned Ablynx more than €83 million. The new program brings the total number of nanobodies in development to 7.

Read more about: .

RELATED ARTICLES
Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in…


Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary ri…


Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, be…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

UGent KU Leuven XpandInnovation Flanders.bio Janssen GSK Biowin Turnstone Itera Life Science V-Bio Ventures

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.